Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein–Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling.

1. Devi, B. C., Pisani, P., Tang, T. S., et al. (2004). High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiology, Biomarkers & Prevention, 13, 482–486.
2. Yu, M. C. (1991). Nasopharyngeal carcinoma: Epidemiology and dietary factors. IARC Scientific Publications, 105, 39–47.
3. Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394–424.
4. Liu, Z., Chang, E. T., Liu, Q., et al. (2017). Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area. Cancer, 123, 2716–2725.
5. Jia, W. H., Feng, B. J., Xu, Z. L., et al. (2004). Familial risk and clustering of nasopharyngeal carcinoma in Guangdong. Cancer, 101, 363–369.
6. Friborg, J., Wohlfahrt, J., Koch, A., et al. (2005). Cancer susceptibility in nasopharyngeal carcinoma families—a population-based cohort study. Cancer Research, 65, 8567–8572.
7. Liu, Z., Fang, F., Chang, E. T., et al. (2015). Cancer risk in the relatives of patients with nasopharyngeal carcinoma: A register-based cohort study in Sweden. British Journal of Cancer, 112, 1827–1831.
8. Armstrong, R. W., Imrey, P. B., Lye, M. S., et al. (1998). Nasopharyngeal carcinoma in Malaysian Chinese: Salted fish and other dietary exposures. International Journal of Cancer, 77, 228–235.
9. Phua, V. C. E., Loo, W. H., Yusof, M. M., et al. (2013). Treatment outcome for nasopharyngeal carcinoma in University Malaya Medical Centre from 2004–2008. Asian Pacific Journal of Cancer Prevention, 14, 4567–4570.
10. El-Sherbieny, E., Rashwan, H., Lubis, S. H., et al. (2011). Prognostic factors in patients with nasopharyngeal carcinoma treated in Hospital Kuala Lumpur. Asian Pacific Journal of Cancer Prevention, 12, 1739–1743.
11. Cheah, S. K., Lau, F. N., Yusof, M. M., et al. (2014). Treatment outcome with brachytherapy for recurrent nasopharyngeal carcinoma. Asian Pacific Journal of Cancer Prevention, 14, 6513–6518.
12. ACTION Study Group, Kimman, M., Jan, S., et al. (2015). Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: Results from a longitudinal study in eight countries. BMC Medicine, 13, 190.
13. Pua, K. C., Khoo, A. S., Yap, Y. Y., et al. (2008). Nasopharyngeal carcinoma database. Medical Journal of Malaysia, 63, 59–62.
14. Stelow, E. B., & Wenig, B. M. (2017). Update from the 4th edition of the World Health Organization classification of head and neck tumours: Nasopharynx. Head and Neck Pathology, 11, 16–22.
15. Yip, T. T., Ngan, R. K., Fong, A. H., et al. (2014). Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncology, 50, 527–538.
16. Liu, Y., Huang, Q., Liu, W., et al. (2012). Establishment of VCA and EBNA1 IgA-based combination by ELISA as preferred screening method for nasopharyngeal carcinoma. International Journal of Cancer, 131, 406–416.
17. Liu, Z., Ji, M. F., Huang, Q. H., et al. (2013). Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening. American Journal of Epidemiology, 177, 242–250.
18. Leung, S. F., Lo, Y. M., Chan, A. T., et al. (2003). Disparity of sensitivities in detection of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma. Clinical Cancer Research, 9, 3431–3434.
19. Yang, X., Dai, W., Kwong, D. L., et al. (2015). Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma. International Journal of Cancer, 136, E127–E135.
20. Chan, K. C. A., Woo, J. K. S., King, A., et al. (2017). Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. New England Journal of Medicine, 377, 513–522.
21. Lam, W. K. J., Jiang, P., Chan, K. C. A., et al. (2018). Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA. Proceedings of the National Academy of Sciences, 115, E5115–E5124.
22. Wagner, P. D., & Srivastava, S. (2012). New paradigms in translational science research in cancer biomarkers. Translational Research, 159, 343–353.
23. Khan, G., & Hashim, M. J. (2014). Global burden of deaths from Epstein-Barr virus attributable malignancies 1990–2010. Infectious Agents and Cancer, 9, 38.
24. Zhang, G., Zong, J., Lin, S., et al. (2015). Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers. International Journal of Cancer, 136, E301–E312.
25. Wang, H. Y., Yan, L. X., Shao, Q., et al. (2014). Profiling plasma microRNA in nasopharyngeal carcinoma. Clinical Chemistry, 60, 773–782.
26. Jiang, C., Chen, J., Xie, S., et al. (2018). Evaluation of circulating EBV microRNA BART2-5p in NPC detection. International Journal of Cancer, 143, 3209–3217.
27. He, B., Zeng, J., Chao, W., et al. (2017). Serum long non-coding RNAs as biomarkers for NPC. Oncotarget, 8, 41166–41177.
28. Zheng, X. H., Cui, C., Ruan, H. L., et al. (2014). Plasma microRNA profiling in nasopharyngeal carcinoma. Chinese Journal of Cancer, 33, 330–338.
29. Gao, W., Wong, T. S., Lv, K. X., et al. (2019). Detection of Epstein-Barr virus-encoded microRNAs in plasma. Head & Neck, 41, 780–792.
30. Liu, X., Luo, H. N., Tian, W. D., et al. (2013). Diagnostic and prognostic value of plasma microRNA deregulation in NPC. Cancer Biology & Therapy, 14, 1133–1142.
31. Gourzones, C., Ferrand, F. R., Amiel, C., et al. (2013). High concentration of viral microRNA BART17 in plasma. Virology Journal, 10, 119.
32. Ramayanti, O., Verkuijlen, S., Novianti, P., et al. (2019). Vesicle-bound EBV-BART13-3p miRNA distinguishes NPC. International Journal of Cancer, 144, 2555–2566.
33. Ooi, C. H., & Mastulu, W. (2009). Epidemiology of cancer in Sarawak 2001–2005. Sarawak Cancer Registry.
34. Maria, S., Nirmal, K., Nafisah, A., et al. (2015). Sabah cancer registry report 2006–2010. Sabah State Health Department.
35. Azizah, A. M., Nor Saleha, I. T., Noor Hashimah, A., et al. (2016). Malaysian National Cancer Registry Report 2007–2011. Ministry of Health Malaysia.
36. Lawrence, J. B., Villnave, C. A., & Singer, R. H. (1988). Sensitive chromatin mapping in situ: EBV copies in lymphoma line. Cell, 52, 51–61.
37. Fryer, J. F., Heath, A. B., Wilkinson, D. E., et al. (2016). WHO International Standard for Epstein-Barr virus. Biologicals, 44, 423–433.
38. Tan, G. W., Khoo, A. S., & Tan, L. P. (2015). Evaluation of RT-qPCR systems for circulating miRNAs. Scientific Reports, 5, 9430.
39. Tan, G. W., & Tan, L. P. (2017). High-throughput RT-qPCR for circulating microRNAs. Methods in Molecular Biology, 1580, 7–19.
40. Stevens, S. J., Verkuijlen, S. A., Hariwiyanto, B., et al. (2005). EBV DNA load in NPC patients. Journal of Clinical Microbiology, 43, 3066–3073.
41. Ryan, J. L., Fan, H., Glaser, S. L., et al. (2004). EBV quantitation by real-time PCR. Journal of Molecular Diagnostics, 6, 378–385.
42. Zhang, W., Chen, Y., Chen, L., et al. (2015). Clinical utility of plasma EBV DNA assays in NPC. Medicine, 94, e845.
43. Zhang, J., Shu, C., Song, Y., et al. (2016). EBV DNA level as prognostic factor in NPC. Medicine, 95, e5130.
44. Lee, V. H. F., Kwong, D. L. W., Leung, T. W., et al. (2018). The addition of pretreatment plasma Epstein-Barr virus DNA into the 8th edition of nasopharyngeal cancer TNM stage classification. International Journal of Cancer, 144, 1713–1722.